Kratom does interact with the same brain receptors that opioids target, and many people report it eases withdrawal symptoms like muscle aches, anxiety, and insomnia. But there’s a significant gap between those anecdotal reports and proven medical evidence. No clinical trials in humans have confirmed kratom is safe or effective for opioid withdrawal, and the FDA has explicitly warned against using it for any medical purpose. Here’s what the science actually shows so far, and what the real risks look like.
How Kratom Interacts With Opioid Receptors
Kratom leaves contain dozens of active compounds, but two do the heavy lifting: mitragynine and 7-hydroxymitragynine. Both bind to the same mu-opioid receptors that drugs like morphine, heroin, and fentanyl activate. That’s the core reason people feel withdrawal relief when they take kratom.
The two compounds work differently, though. Mitragynine, which makes up the bulk of kratom’s alkaloid content, actually acts as a blocker at the mu-opioid receptor rather than an activator. It binds weakly compared to traditional opioids. 7-hydroxymitragynine is the more potent one, with roughly nine times the binding strength of mitragynine at the mu receptor. It acts as a partial activator, meaning it stimulates the receptor but only produces about 41% of the maximum response a full opioid would. That partial activation is similar in concept to how buprenorphine (the active ingredient in Suboxone) works: enough receptor stimulation to take the edge off withdrawal, but not enough to produce the full high of a stronger opioid.
This partial-activation profile is why researchers find kratom interesting for withdrawal. A controlled animal study at the University of Florida found that kratom tea significantly reduced withdrawal symptoms in morphine-dependent animals, even at low doses. The pain relief and withdrawal effects were traced directly to mu-opioid receptor activity. But animal results don’t always translate to humans, and no equivalent controlled trial has been done in people.
What People Actually Experience
Without formal clinical trials, most of what we know about kratom for withdrawal comes from case reports and surveys. People who use kratom to manage opioid withdrawal typically describe relief from the most punishing symptoms: the deep muscle aches, restlessness, nausea, diarrhea, and insomnia that make the first week of detox so brutal. Some also report reduced cravings, which is arguably more important for long-term recovery than symptom relief alone.
The doses people use vary enormously. Published case reports document a wide range, from as little as 4 grams per day to over 100 grams per day in heavy users. Many people start at moderate doses (roughly 7 to 15 grams daily) and either taper down or escalate over time. There are no standardized dosing guidelines because kratom is sold as a supplement or raw plant material, not a regulated medication. Potency varies between products, vendors, and even batches, so two people taking “the same amount” may get very different effects.
Kratom Can Create Its Own Dependence
This is the part that catches many people off guard. Because kratom activates opioid receptors, regular use can lead to physical dependence on kratom itself. When people try to stop, they experience a withdrawal syndrome that looks a lot like opioid withdrawal: nausea, chills, body aches, insomnia, anxiety, irritability, and depression.
There’s one important difference in timing. Standard opioid withdrawal typically peaks within a few days and largely resolves within a week. Kratom withdrawal can persist for much longer, with some cases dragging on for up to three months after the last dose. That prolonged timeline can make it harder to quit than people expect when they first start using kratom as a stopgap.
Case series published in the Journal of Addiction Medicine document patients who originally started kratom to manage opioid cravings or withdrawal, only to develop heavy kratom dependence requiring medical treatment. Patients using more than 40 grams per day needed higher doses of prescription medications to manage their kratom withdrawal than those using under 20 grams per day. In other words, the deeper you get into kratom use, the harder it is to come off.
Known Safety Risks
The FDA warns against kratom use due to the risk of liver toxicity, seizures, and substance use disorder. These aren’t theoretical concerns.
A review from the U.S. Drug Induced Liver Injury Network identified 11 confirmed cases of liver damage attributed to kratom between 2003 and 2019, representing about 3% of all supplement-related liver injuries tracked during that period. All 11 patients developed jaundice, with liver enzyme levels rising to several times the normal range. While 11 cases over 16 years may sound rare, kratom liver injuries have increased in recent years as use has grown, and mild cases likely go unreported or unrecognized.
Seizures are another documented risk, though precise incidence data is limited. The risk appears to increase at higher doses and when kratom is combined with other substances. Because kratom products are unregulated, contamination with other compounds is also a concern.
How It Compares to Approved Treatments
Three medications are FDA-approved for opioid use disorder: buprenorphine (often combined with naloxone as Suboxone), methadone, and naltrexone. All three have been studied extensively in large clinical trials, with well-established safety profiles and dosing guidelines. Kratom has none of that evidence base.
The comparison to buprenorphine is especially relevant because both are partial opioid receptor activators. But buprenorphine is manufactured to precise standards, prescribed at specific doses, and monitored by a clinician. Kratom’s potency is unpredictable, its long-term effects are poorly understood, and no medical professional is overseeing the process when someone self-treats with it.
No head-to-head study has compared kratom to buprenorphine or methadone for managing withdrawal or preventing relapse. The American Society of Addiction Medicine has begun educating providers about kratom, encouraging them to screen patients for use and become familiar with its effects, but has not endorsed it as a treatment.
The Regulatory Picture
Kratom occupies a legal gray zone in the United States. It is not FDA-approved to treat any medical condition, and no kratom-containing drug products are legally on the market. The FDA has encouraged drug companies interested in kratom-derived therapies to pursue formal development through the standard approval process, but no one has completed that path yet.
Kratom remains legal at the federal level, though several states and municipalities have banned or restricted it. It is widely available online and in smoke shops, gas stations, and specialty stores. This easy access is part of why so many people try it for withdrawal on their own, without medical guidance.
What This Means Practically
Kratom’s pharmacology gives a plausible reason why it might ease opioid withdrawal. The partial activation of mu-opioid receptors could reduce symptoms without producing the full effects of stronger opioids. But “plausible” is not “proven,” and the gap matters. The lack of standardized products means you can’t know exactly what you’re taking. The risk of developing kratom dependence is real, and the withdrawal from kratom itself can last months. Liver injury and seizures, while uncommon, are documented.
People who are already using kratom to manage withdrawal or cravings should know that medical providers are increasingly familiar with it. Case reports suggest that transitioning from kratom to buprenorphine-based treatment is feasible, with dosing guided by how much kratom someone has been taking. Those using less than 20 grams daily tend to stabilize on lower doses of buprenorphine, while heavy users above 40 grams daily may need significantly more.